From left: Cara CEO Derek Chalmers and board member Christopher Posner

Weeks in­to first ap­proval, Cara waves good­bye to found­ing CEO in fa­vor of board mem­ber

A biotech’s first drug ap­proval is a process of­ten years in the mak­ing and a crown­ing achieve­ment for founder-CEOs who have run the race from the be­gin­ning. Af­ter 17 years watch­ing Cara Ther­a­peu­tics grow to a com­mer­cial brand, this biotech’s found­ing CEO is now ready to move on to his next phase.

Cara has ap­point­ed Christo­pher Pos­ner, a cur­rent board mem­ber and for­mer CEO of Leo Phar­ma’s US branch, as its next leader, re­plac­ing found­ing CEO Derek Chalmers, the com­pa­ny said Wednes­day. Chalmers will move over in­to a se­nior ad­vi­so­ry role, with Pos­ner set to take on the man­tle Nov. 9.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA